Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourDescending Triangle
15 minLeaning Bullish
5 minSymmetric Triangle
Daily trend turns up above $1.20
Key levels
Resistance$1.01
Resistance$0.91
Support$0.78
Support$0.66
Latest news & SEC filings
AnalystTD Cowen keeps Buy rating on Stereotaxis, cuts price target to $2
EarningsStereotaxis Posts Q3 2026 Results
DealStereotaxis secures up to $24 million through convertible notes
All STXS news →Stereotaxis develops robotic systems for use in cardiac electrophysiology and other endovascular procedures. Its offerings include magnetic navigation platforms such as Genesis RMN and Niobe, along with disposable catheters, guidewires, and interventional devices. The company also provides integration and imaging technologies, including the Odyssey portfolio. Its customers are hospitals, electrophysiologists, and interventional physicians, primarily in the United States, Europe, and other international markets.
Based on the company's 10-K filed Mar 12, 2026.
NYSE · Healthcare
SEPT Low Target
$3.00
SEPT Mid Target
$3.00
SEPT High Target
$3.50
Analyst Consensus
$3.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for STXS.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$2.33
34
Moat Score
NONE
5/9
Piotroski Score
-14.4
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
20.3%
3yr Revenue CAGR
4.8%
EPS Growth YoY
16.67%
FCF Growth YoY
-61.5%
Revenue Trend
ACCELERATING
SEPT Investing tracks real-time dark pool institutional trades for STXS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 23:14:21 | $0.86 | 1,000 | $$861 | SELL |
| 20:59:39 | $0.90 | 4,400 | $$4K | BUY |
| 20:59:39 | $0.90 | 5,600 | $$5K | BUY |
| 20:59:28 | $0.90 | 7,500 | $$7K | BUY |
| 20:59:26 | $0.90 | 1,076 | $$968 | SELL |
5 dark pool trades shown · $$18K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT Investing provides real-time options flow tracking for STXS, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $2.5 | May 21 | 191 | $$2000 | 200 | BLOCK |
| CALL | $2.5 | May 21 | 191 | $$3000 | 200 | BLOCK |
2 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Stereotaxis, Inc. (STXS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Stereotaxis, Inc. (STXS) is at $0.90, down 12.62% (-$0.13) at the Nov 11, 2026 close.
Latest STXS news — Nov 11, 2026: TD Cowen keeps Buy rating on Stereotaxis, cuts price target to $2 · Nov 11, 2026: Stereotaxis Posts Q3 2026 Results
Stereotaxis shares closed at $0.88, up 0.49% on the day, after the company reported first-in-human data on Robocath's new robotic system. The announcement highlighted that the Robocath robotic system achieved a 100% clinical success rate and a 95% technical success rate at a cardiovascular medical meeting.
The average analyst price target for STXS is $3.00, ranging from $3 to $4, based on 3 analysts. Latest: Citizens maintains on Aug 27, 2026.
Analyst ratings for STXS: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
STXS last reported on Aug 11, 2026: EPS -$0.05 vs -$0.05 expected — in line.
STXS does not currently pay a dividend.
Support: $0.78, $0.66, $0.54. Resistance: $0.91, $1.01, $1.20.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 11, 2026: TD Cowen keeps Buy rating on Stereotaxis, cuts price target to $2 · Nov 11, 2026: Stereotaxis Posts Q3 2026 Results · Nov 11, 2026: Stereotaxis secures up to $24 million through convertible notes